Anagenex appoints to its Board of Directors, Robert Forrester as Executive Chairman alongside Isaac Ro as Board member

– USA, MA –  Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary AI to discover the next generation of small molecule medicines, today announced the appointment of Robert Forrester as Executive Chairman of its Board of Directors, while Isaac Ro also joined the Board of Directors.

About Robert Forrester

Robert Forrester is a life sciences executive and entrepreneur with more than 20 years of experience leading both public and private companies including EQRx, Verastem Oncology, Forma Therapeutics, CombinatoRx, and Coley (acquired by Pfizer). He has co-founded 8 companies including IDRx and EQRx. Earlier in his career, Robert worked for several investment banks undertaking M&A and finance transactions and served as a managing director of the Proprietary Investment Group at MeesPierson investing in life science companies.

Robert Forrester holds an LL.B. from Bristol University, UK.

About Isaac Ro

Isaac Ro has extensive experience as an investor, board member, and operator having navigated multiple financings, M&A transactions, and exits. Isaac is currently a Partner at Catalio Capital Management, LP, where he helps lead the private investments team. He previously served as Executive Chairman of Haystack Oncology (sold to Quest Diagnostics), CFO of Sema4 (took public NASDAQ: WGS, and acquired GeneDx), and CFO of Thrive Earlier Detection (sold to Exact Sciences). Previously, he was an equity research analyst at Goldman Sachs and Leerink Partners.

Isaac Ro holds a B.A. in History from Middlebury College.

About Anagenex

Anagenex is pairing high-quality, large-scale data generation with AI to discover the next generation of small-molecule medicines. Driven by over 100 billion proprietary measurements, Anagenex’s platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks, creating a virtuous cycle between real lab experiments and computational tools. Led by a team of highly experienced scientists and engineers, the company’s pipeline is focused on synthetic lethal oncology.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.